Related Experiment Video

Updated: Jun 23, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets

Aniello Cerrato1, Valentina De Falco, Massimo Santoro

  • 1Istituto di Endocrinologia ed Oncologia Sperimentale CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, L. Califano, Università Federico II di Napoli, Naples, Italy.

Journal of Molecular Endocrinology
|April 23, 2009
PubMed

Insights

Medullary thyroid carcinoma (MTC) is a rare cancer. This review explores genetic mutations in RET and RB1/TP53 pathways, crucial for understanding MTC development and improving targeted therapies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from C-cells.
  • Metastatic MTC is currently incurable due to resistance to conventional therapies like chemotherapy and radiotherapy.
  • The REarranged during Transfection (RET) proto-oncogene is implicated in MTC pathogenesis, but mutations are absent in about half of sporadic cases.

Purpose of the Study:

  • To review current data on genetic alterations in MTC.
  • To investigate the role of the RET proto-oncogene and tumor suppressor pathways (RB1 and TP53) in MTC development.
  • To highlight the importance of understanding genetic lesions for identifying novel therapeutic targets.

Main Methods:

  • Literature review of studies on genetic pathways in Medullary Thyroid Carcinoma.
  • Analysis of data from mouse models and human samples.
  • Synthesis of information on RET, RB1, and TP53 pathway involvement in MTC.

Main Results:

  • The RET proto-oncogene is a key driver in MTC, but alternative genetic pathways exist.
  • Evidence suggests involvement of the RB1 (retinoblastoma) and TP53 tumor-suppressor pathways in MTC formation.
  • Genetic lesions in these pathways are critical for understanding MTC etiology.

Conclusions:

  • Understanding the genetic landscape of MTC, including RET and other pathways like RB1/TP53, is essential.
  • Identifying these genetic alterations is a prerequisite for developing effective molecular therapies.
  • Further research into these genetic lesions can improve the efficacy of existing RET-targeted therapies.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...